Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects.

Moller L, Norrelund H, Jessen N, Flyvbjerg A, Pedersen SB, Gaylinn BD, Liu J, Thorner MO, Moller N, Lunde Jorgensen JO

The Journal of clinical endocrinology and metabolism9 Oct 2009Cited by 31 (Europe PMC)

PMID19820031PMCIDPMC2775657DOI10.1210/jc.2009-0381PepBankPUB-19820031

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In fasting healthy men, pegvisomant reduced circulating free fatty acids versus saline (1226 versus 1074 micromol/liter, P = 0.03).
In plain wordsIn fasting healthy men, pegvisomant lowered circulating free fatty acids compared with saline.
Peptide
Pegvisomant
Outcome
DecreaseBasal circulating free fatty acids
Study
n = 10
Comparator
Saline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Measurements
Free fatty acids
1226 micromol/liter
saline
Free fatty acids
1074 micromol/liter
pegvisomant
Source sentences
Summary
GHR blockade significantly suppressed circulating free fatty acids (1226 +/- 83 vs. 1074 +/- 65 micromol/liter; P = 0.03)
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, crossover study in 10 healthy young men.InterventionAfter 36 h of fasting with saline or pegvisomant (GHR blockade), the subjects were studied during a 4-h basal period and 2.5-h hyperinsulinemic euglycemic clamp.
Report a problemFND-1982003101
02HumanRandomized controlled trialEfficacy outcome
In fasting healthy men, pegvisomant reduced circulating ketone bodies versus saline (3080 versus 2015 micromol/liter, P <or= 0.01).
In plain wordsIn fasting healthy men, pegvisomant lowered ketone bodies compared with saline.
Peptide
Pegvisomant
Outcome
DecreaseBasal ketone bodies
Study
n = 10
Comparator
Saline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Measurements
Ketone bodies
3080 micromol/liter
saline
Ketone bodies
2015 micromol/liter
pegvisomant
Source sentences
Summary
and ketone bodies (3080 +/- 271 vs. 2015 +/- 235 micromol/liter; P <or= 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, crossover study in 10 healthy young men.InterventionAfter 36 h of fasting with saline or pegvisomant (GHR blockade), the subjects were studied during a 4-h basal period and 2.5-h hyperinsulinemic euglycemic clamp.
Report a problemFND-1982003102
03HumanRandomized controlled trialEfficacy outcome
In fasting healthy men, pegvisomant reduced forearm free fatty acid uptake versus saline (0.341 versus 0.004 micromol/100 ml x min).
In plain wordsIn fasting healthy men, pegvisomant lowered forearm free fatty acid uptake compared with saline.
Peptide
Pegvisomant
Outcome
DecreaseBasal forearm free fatty acid uptake
Study
n = 10
Comparator
Saline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Measurements
Free fatty acid uptake
0.341 micromol/100 ml x min
saline
Free fatty acid uptake
0.004 micromol/100 ml x min
pegvisomant
Source sentences
Summary
as well as forearm uptake of free fatty acids (0.341 +/- 0.150 vs. 0.004 +/- 0.119 micromol/100 ml x min; P < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, crossover study in 10 healthy young men.InterventionAfter 36 h of fasting with saline or pegvisomant (GHR blockade), the subjects were studied during a 4-h basal period and 2.5-h hyperinsulinemic euglycemic clamp.
Report a problemFND-1982003103
04HumanRandomized controlled trialEfficacy outcome
In fasting healthy men, pegvisomant reduced lipid oxidation versus saline (1.3 versus 1.2 mg/kg x min, P = 0.03).
In plain wordsIn fasting healthy men, pegvisomant lowered lipid oxidation compared with saline.
Peptide
Pegvisomant
Outcome
DecreaseBasal lipid oxidation
Study
n = 10
Comparator
Saline
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Measurements
Lipid oxidation
1.3 mg/kg x min
saline
Lipid oxidation
1.2 mg/kg x min
pegvisomant
Source sentences
Summary
and lipid oxidation (1.3 +/- 0.1 vs. 1.2 +/- 0.1 mg/kg x min; P = 0.03) in the basal period.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, crossover study in 10 healthy young men.InterventionAfter 36 h of fasting with saline or pegvisomant (GHR blockade), the subjects were studied during a 4-h basal period and 2.5-h hyperinsulinemic euglycemic clamp.
Report a problemFND-1982003104
05HumanRandomized controlled trialEfficacy outcome
In fasting healthy men, pegvisomant did not affect serum IGF-I versus saline.
In plain wordsIn fasting healthy men, pegvisomant did not change serum IGF-I compared with saline.
Peptide
Pegvisomant
Outcome
No significant changeSerum IGF-I
Study
n = 10
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
By contrast, IGF-I levels in either serum or peripheral tissues were not impacted by GHR blockade, and protein metabolism was also unaffected.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, crossover study in 10 healthy young men.InterventionAfter 36 h of fasting with saline or pegvisomant (GHR blockade), the subjects were studied during a 4-h basal period and 2.5-h hyperinsulinemic euglycemic clamp.
Report a problemFND-1982003105
06HumanRandomized controlled trialEfficacy outcome
In fasting healthy men, pegvisomant did not affect peripheral tissue IGF-I versus saline.
In plain wordsIn fasting healthy men, pegvisomant did not change tissue IGF-I compared with saline.
Peptide
Pegvisomant
Outcome
No significant changePeripheral tissue IGF-I
Study
n = 10
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
By contrast, IGF-I levels in either serum or peripheral tissues were not impacted by GHR blockade, and protein metabolism was also unaffected.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, crossover study in 10 healthy young men.InterventionAfter 36 h of fasting with saline or pegvisomant (GHR blockade), the subjects were studied during a 4-h basal period and 2.5-h hyperinsulinemic euglycemic clamp.
Report a problemFND-1982003106
07HumanRandomized controlled trialEfficacy outcome
In fasting healthy men, pegvisomant did not affect protein metabolism versus saline.
In plain wordsIn fasting healthy men, pegvisomant did not change protein metabolism compared with saline.
Peptide
Pegvisomant
Outcome
No significant changeProtein metabolism
Study
n = 10
Comparator
Saline
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
By contrast, IGF-I levels in either serum or peripheral tissues were not impacted by GHR blockade, and protein metabolism was also unaffected.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, crossover study in 10 healthy young men.InterventionAfter 36 h of fasting with saline or pegvisomant (GHR blockade), the subjects were studied during a 4-h basal period and 2.5-h hyperinsulinemic euglycemic clamp.
Report a problemFND-1982003107
08HumanRandomized controlled trialEfficacy outcome
In fasting healthy men, pegvisomant elevated basal glucose versus saline.
In plain wordsIn fasting healthy men, pegvisomant raised basal blood glucose compared with saline.
Peptide
Pegvisomant
Outcome
IncreaseBasal glucose
Study
n = 10
Comparator
Saline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Basal glucose levels were elevated by GHR blockade, but insulin sensitivity was similar; this was associated with an increased acyl/desacyl ghrelin ratio.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, crossover study in 10 healthy young men.InterventionAfter 36 h of fasting with saline or pegvisomant (GHR blockade), the subjects were studied during a 4-h basal period and 2.5-h hyperinsulinemic euglycemic clamp.
Report a problemFND-1982003108
09HumanRandomized controlled trialEfficacy outcome
In fasting healthy men, insulin sensitivity was similar with pegvisomant and saline.
In plain wordsIn fasting healthy men, insulin sensitivity was similar with pegvisomant and saline.
Peptide
Pegvisomant
Outcome
Direction not reportedInsulin sensitivity
Study
n = 10
Comparator
Saline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Basal glucose levels were elevated by GHR blockade, but insulin sensitivity was similar; this was associated with an increased acyl/desacyl ghrelin ratio.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, crossover study in 10 healthy young men.InterventionAfter 36 h of fasting with saline or pegvisomant (GHR blockade), the subjects were studied during a 4-h basal period and 2.5-h hyperinsulinemic euglycemic clamp.
Report a problemFND-1982003109
10HumanRandomized controlled trialEfficacy outcome
In fasting healthy men, pegvisomant was associated with an increased acyl/desacyl ghrelin ratio versus saline.
In plain wordsIn fasting healthy men, pegvisomant was associated with a higher acyl/desacyl ghrelin ratio than saline.
Peptide
Pegvisomant
Outcome
IncreaseAcyl/desacyl ghrelin ratio
Study
n = 10
Comparator
Saline
Outcome group
Appetite and food intake · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Basal glucose levels were elevated by GHR blockade, but insulin sensitivity was similar; this was associated with an increased acyl/desacyl ghrelin ratio.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, placebo-controlled, crossover study in 10 healthy young men.InterventionAfter 36 h of fasting with saline or pegvisomant (GHR blockade), the subjects were studied during a 4-h basal period and 2.5-h hyperinsulinemic euglycemic clamp.
Report a problemFND-1982003110

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT02152124

Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?

University Hospital, Ghentn = 211 Jun 2014 to 31 Aug 2017

Acromegaly

Trial page ClinicalTrials.govUpdated 29 Dec 2022

CompletedNot applicableNCT00476879

Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content

University of Aarhusn = 10Aug 2006 to Jun 2008

Metabolism · Fatty Liver

Trial page ClinicalTrials.govUpdated 12 Aug 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.